Welcome to our dedicated page for Aptose Bioscienc SEC filings (Ticker: APTOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aptose Biosciences Inc. (APTOF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Canadian issuer reporting to the U.S. Securities and Exchange Commission. Aptose files current reports on Form 8-K under Commission File Number 001-32001, alongside its Canadian securities filings. These documents are central for investors who want to understand the company’s clinical-stage oncology business, financial condition, and pending corporate transactions.
For Aptose, Form 8-K filings are particularly important. Recent 8-Ks include Regulation FD disclosures that furnish press releases about tuspetinib (TUS) clinical data from the TUSCANY Phase 1/2 trial, including safety, complete remission (CR/CRh) rates, and minimal residual disease (MRD) findings in acute myeloid leukemia (AML). Other 8-Ks report quarterly financial results, detailing research and development expenses by program, general and administrative costs, cash balances, and the company’s reliance on loan facilities from Hanmi Pharmaceutical Co. Ltd. to fund operations.
Another critical category of filings relates to material definitive agreements and corporate transactions. Aptose has filed an 8-K describing its definitive arrangement agreement with Hanmi and HS North America Ltd., under which a Hanmi subsidiary will acquire all Aptose common shares not already owned or controlled by Hanmi or its affiliates, subject to shareholder and court approvals. That filing outlines the transaction structure, consideration for minority shareholders, required approvals, and the expectation that, after completion, Aptose will no longer be subject to certain reporting requirements and its shares will be delisted from stock exchanges including the TSX.
Through Stock Titan, investors can review these filings and use AI-powered summaries to interpret key sections, such as risk factor discussions, forward-looking statements, and the implications of financing and transaction agreements. The platform also tracks new 8-Ks in real time, helping users monitor Aptose’s ongoing clinical disclosures, financial updates, and progress toward the proposed acquisition.
Aptose Biosciences Inc. filed its Q3 2025 report, highlighting ongoing development of tuspetinib while facing significant financial strain. The company reported a net loss of $5.1 million for the quarter and $17.7 million for the nine months. Cash, cash equivalents and restricted cash were $1.6 million as of September 30, 2025, with cash used in operations of $16.1 million year‑to‑date. Management states that conditions raise substantial doubt about the Company’s ability to continue as a going concern.
To fund operations, Aptose relied on related‑party facilities with Hanmi: an $8.5 million facility fully drawn and an additional up to $11.9 million facility, of which $4.2 million was advanced by October 27, 2025. Loan payable to related party rose to $18.7 million. Shareholders’ deficit widened to $(19.5) million. The company effected a 1‑for‑30 reverse stock split on February 26, 2025 and used an ATM to raise $1.0 million gross. 2,552,429 common shares were outstanding as of November 7, 2025.
Aptose Biosciences Inc. filed a Form 8-K to furnish a press release covering its results of operations and financial condition. The press release, dated November 13, 2025, is attached as Exhibit 99.1 and is incorporated by reference for informational purposes.
The company states that the Exhibit 99.1 information is being furnished under the Exchange Act and will not be deemed filed under Section 18, nor automatically incorporated into Securities Act or Exchange Act filings unless specifically referenced.
Aptose Biosciences Inc. furnished a press release under Item 7.01 (Regulation FD) via a Form 8-K. The release is attached as Exhibit 99.1 and incorporated by reference in this report.
Consistent with General Instruction B.2, the Item 7.01 information is deemed furnished, not filed, and is not incorporated by reference into Securities Act or Exchange Act filings unless expressly stated by specific reference.
Aptose Biosciences Inc. filed a current report to furnish a press release issued on October 16, 2025. The company is using this filing to make the press release publicly available under Regulation FD, which is intended to provide fair disclosure of information to all investors at the same time. The press release itself is attached as Exhibit 99.1 and is incorporated by reference only as specifically indicated in future filings.
Aptose Biosciences Inc. filed a current report to furnish information under Regulation FD. On September 22, 2025, the company issued a press release, which is attached to the report as Exhibit 99.1 and incorporated by reference. The company notes that this press release is being furnished under Item 7.01 of the Exchange Act and is not deemed “filed” for liability purposes under Section 18 or automatically incorporated into other securities law filings.
Aptose Biosciences Inc. filed a current report to furnish information under Regulation FD. On September 22, 2025, the company issued a press release, which is attached to the report as Exhibit 99.1 and incorporated by reference. The company notes that this press release is being furnished under Item 7.01 of the Exchange Act and is not deemed “filed” for liability purposes under Section 18 or automatically incorporated into other securities law filings.